These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 17304175)

  • 1. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
    Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
    Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.
    Drulovic J; Ivanovic J; Mesaros S; Martinovic V; Kisic-Tepavcevic D; Dujmovic I; Pekmezovic T
    Neurol Sci; 2019 Aug; 40(8):1627-1636. PubMed ID: 31011930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.
    Gasperi C; Salmen A; Antony G; Bayas A; Heesen C; Kümpfel T; Linker RA; Paul F; Stangel M; Tackenberg B; Bergh FT; Warnke C; Weber F; Wiendl H; Wildemann B; Zettl UK; Ziemann U; Zipp F; Tumani H; Gold R; Hemmer B;
    JAMA Neurol; 2019 Jul; 76(7):841-849. PubMed ID: 31034002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
    Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
    Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
    Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.